After confirming that VEGF was an independent prognostic factor for patients receiving TACE, we also revealed that, when baseline serum VEGF < 189.79 pg/mL, the risk of death increased in HCC patients with increasing concentrations of VEGF. Here, VEGFA is linked to hepatocellular carcinoma.